Sign in with your email address username.


[Editorial] Paying a high price for cancer drugs

Results of research from the early Breast Cancer Triallists’ Collaborative Group in Oxford, UK, published in The Lancet on July 24, 2015, were encouraging. They showed that use of adjuvant bisphosphonates in the treatment of early breast cancer in postmenopausal women could reduce disease recurrence and mortality. Bisphosphonates, available in generic form, are inexpensive and should be available worldwide to improve care in this population.